Skip to main content

Table 1 Inclusion and exclusion criteria

From: Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)

Inclusion criteria Exclusion criteria
• Age ≥ 18 years old and ≤ 80 years old • Metastatic pancreatic cancer
• Histological proven pancreatic adenocarcinoma • Patients who had surgeries, chemotherapy or other treatments before inclusion
• Borderline resectable pancreatic cancer proven by imaging examinations via multidisciplinary approaches according to NCCN guidelines • Impaired organ functions:
A. Heart failure (New York Heart Association III–IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia
B. Respiratory failure
• No prior chemotherapy or radiotherapy • Confirmed other cancer within 5 years
• ECOG of 0 or 1 • Pregnant women or lactating women
• Routine blood test: absolute neutrophil count> 1500/mm3, platelet> 100,000/mm3 • Patients enrolled in other clinical trials or incompliant of regular follow up
• Normal liver function: serum total bilirubin≤2 .0mg/dl, ALT and AST < 2.5 times of the upper limit of normal value • Patients who did not provide an informed consent
• Normal kidney function: serum creatinine< 1.5 times of the upper limit of normal value or creatinine clearance rate > 45 ml/min  
• No severe comorbidities